AU2014337391B2 - Combination therapies with PSMA ligand conjugates - Google Patents

Combination therapies with PSMA ligand conjugates Download PDF

Info

Publication number
AU2014337391B2
AU2014337391B2 AU2014337391A AU2014337391A AU2014337391B2 AU 2014337391 B2 AU2014337391 B2 AU 2014337391B2 AU 2014337391 A AU2014337391 A AU 2014337391A AU 2014337391 A AU2014337391 A AU 2014337391A AU 2014337391 B2 AU2014337391 B2 AU 2014337391B2
Authority
AU
Australia
Prior art keywords
psma
cancer cells
antiandrogen
cells
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014337391A
Other languages
English (en)
Other versions
AU2014337391A1 (en
Inventor
Vincent Dipippo
William C. Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PSMA Development Co LLC
Original Assignee
PSMA Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PSMA Development Co LLC filed Critical PSMA Development Co LLC
Priority claimed from PCT/US2014/000124 external-priority patent/WO2015057250A1/en
Publication of AU2014337391A1 publication Critical patent/AU2014337391A1/en
Priority to AU2020203191A priority Critical patent/AU2020203191B2/en
Application granted granted Critical
Publication of AU2014337391B2 publication Critical patent/AU2014337391B2/en
Priority to AU2023200926A priority patent/AU2023200926A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014337391A 2013-10-18 2014-05-14 Combination therapies with PSMA ligand conjugates Active AU2014337391B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203191A AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates
AU2023200926A AU2023200926A1 (en) 2013-10-18 2023-02-17 Combination therapies with psma ligand conjugates

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361893145P 2013-10-18 2013-10-18
US61/893,145 2013-10-18
US201361903589P 2013-11-13 2013-11-13
JP2013235506A JP6908964B2 (ja) 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法
US61/903,589 2013-11-13
JP2013-235506 2013-11-13
PCT/US2014/000124 WO2015057250A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203191A Division AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates

Publications (2)

Publication Number Publication Date
AU2014337391A1 AU2014337391A1 (en) 2016-05-05
AU2014337391B2 true AU2014337391B2 (en) 2020-06-11

Family

ID=53009949

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014337391A Active AU2014337391B2 (en) 2013-10-18 2014-05-14 Combination therapies with PSMA ligand conjugates
AU2020203191A Active AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates
AU2023200926A Abandoned AU2023200926A1 (en) 2013-10-18 2023-02-17 Combination therapies with psma ligand conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203191A Active AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates
AU2023200926A Abandoned AU2023200926A1 (en) 2013-10-18 2023-02-17 Combination therapies with psma ligand conjugates

Country Status (4)

Country Link
EP (2) EP3827844A1 (https=)
JP (3) JP6908964B2 (https=)
AU (3) AU2014337391B2 (https=)
CA (2) CA2927735C (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020077259A1 (en) * 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
CN119792549A (zh) * 2021-04-23 2025-04-11 天津全和诚生物技术有限公司 缀合物及其制备方法和用途
WO2025125469A1 (en) * 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
WO2025216238A1 (ja) * 2024-04-09 2025-10-16 国立大学法人広島大学 薬物コンジュゲート又はその塩

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002222A2 (en) * 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
EP2326350B1 (en) * 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
AU2010260195B2 (en) 2009-06-15 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002222A2 (en) * 2005-06-20 2007-01-04 Psma Development Company, Llc Psma antibody-drug conjugates

Also Published As

Publication number Publication date
JP2023135666A (ja) 2023-09-28
JP2019194209A (ja) 2019-11-07
CA2927735C (en) 2023-02-07
CA3181096A1 (en) 2015-04-23
EP3057614B1 (en) 2020-09-30
AU2014337391A1 (en) 2016-05-05
EP3827844A1 (en) 2021-06-02
JP2015078168A (ja) 2015-04-23
JP7716836B2 (ja) 2025-08-01
AU2020203191B2 (en) 2023-03-09
CA2927735A1 (en) 2015-04-23
JP6908964B2 (ja) 2021-07-28
AU2023200926A1 (en) 2023-03-23
EP3057614A1 (en) 2016-08-24
AU2020203191A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
AU2020203191B2 (en) Combination therapies with psma ligand conjugates
US20150110814A1 (en) Combination therapies with psma ligand conjugates
US20250195701A1 (en) Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
US9242012B2 (en) Methods for killing PSMA-expressing, taxane-resistant cancer cells
EP1912677B1 (en) PSMA antibody-drug conjugates
Oflazoglu et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker
JP2022017295A (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
JP2019506136A (ja) 新規抗ｅｍｒ２抗体及び使用方法
CA3151322A1 (en) Combination therapy with immune stimulatory conjugates
Masuda et al. CD30-targeting immunoconjugates and bystander effects
Anderson et al. Antibody-drug conjugates: an evolving approach for melanoma treatment
ES2837927T3 (es) Terapias de combinación con conjugados de ligando de PSMA
CA3199259A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
Orlowski Tumor response under treatment with the microtubule stabilizing agent patupilone and ionizing radiation
HK1116697B (en) Psma antibody-drug conjugates
HK1159474B (en) Compounds for killing psma-expressing, taxane- resistant cancer cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)